Nahm, C.B.; Turchini, J.; Sahni, S.; Moon, E.; Itchins, M.; Arena, J.; Chou, A.; Colvin, E.K.; Howell, V.M.; Pavlakis, N.;
et al. The Right Treatment Strategy for the Right Patient: A Biomarker-Driven Approach to Neoadjuvant vs. Surgery-First Management of Resectable and Borderline Resectable Pancreatic Cancer. Cancers 2022, 14, 3620.
https://doi.org/10.3390/cancers14153620
AMA Style
Nahm CB, Turchini J, Sahni S, Moon E, Itchins M, Arena J, Chou A, Colvin EK, Howell VM, Pavlakis N,
et al. The Right Treatment Strategy for the Right Patient: A Biomarker-Driven Approach to Neoadjuvant vs. Surgery-First Management of Resectable and Borderline Resectable Pancreatic Cancer. Cancers. 2022; 14(15):3620.
https://doi.org/10.3390/cancers14153620
Chicago/Turabian Style
Nahm, Christopher B., John Turchini, Sumit Sahni, Elizabeth Moon, Malinda Itchins, Jennifer Arena, Angela Chou, Emily K. Colvin, Viive M. Howell, Nick Pavlakis,
and et al. 2022. "The Right Treatment Strategy for the Right Patient: A Biomarker-Driven Approach to Neoadjuvant vs. Surgery-First Management of Resectable and Borderline Resectable Pancreatic Cancer" Cancers 14, no. 15: 3620.
https://doi.org/10.3390/cancers14153620
APA Style
Nahm, C. B., Turchini, J., Sahni, S., Moon, E., Itchins, M., Arena, J., Chou, A., Colvin, E. K., Howell, V. M., Pavlakis, N., Clarke, S., Samra, J. S., Gill, A. J., & Mittal, A.
(2022). The Right Treatment Strategy for the Right Patient: A Biomarker-Driven Approach to Neoadjuvant vs. Surgery-First Management of Resectable and Borderline Resectable Pancreatic Cancer. Cancers, 14(15), 3620.
https://doi.org/10.3390/cancers14153620
